Partner
M. David Weingarten, Ph.D., managing partner of Finnegan's Atlanta office, is a nationally recognized intellectual property (IP) attorney who helps pharmaceutical, biotechnology, and chemical companies protect and maximize the value of their most important innovations. He represents clients in high-stakes patent litigation, proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), and patent prosecution matters. Drawing on his experience as a scientist, pharmaceutical industry veteran, and patent lawyer, David brings a distinct depth of technical understanding to complex matters involving pharmaceuticals, biologics, formulations, chemical processes, and other life sciences technologies.
David advises clients ranging from emerging biotechnology companies to global pharmaceutical, biotechnology, and chemical industry leaders on protecting breakthrough technologies, navigating complex patent disputes, and maximizing the value of their IP assets. He assists clients throughout the IP life cycle, from securing and strengthening patent protection to enforcing patent rights and defending against infringement claims.
Clients value David’s practical, strategic counsel and his ability to quickly grasp complex technologies and develop effective solutions. His practice includes patent litigation, PTAB proceedings, patent prosecution, portfolio development, freedom-to-operate (FTO) analyses, due diligence, and strategic IP counseling.
Few patent attorneys combine David’s depth of pharmaceutical industry experience with extensive patent litigation, PTAB, and prosecution experience. Before entering private practice, he spent more than a decade leading research, development, manufacturing, and technology transfer initiatives in the pharmaceutical industry. He worked across multiple therapeutic areas and played key roles in drug discovery, process development, regulatory submissions, and strategic due diligence efforts. This experience enables him to work seamlessly with scientists, inventors, executives, and in-house counsel while providing practical insight into sophisticated patent and technology issues.
David is widely recognized as one of the nation's leading life sciences patent attorneys. LMG Life Sciences named him Patent Strategy Attorney of the Year, South, and has recognized him for excellence in Patent Prosecution and Patent Strategy & Management. He is a Patent Star (National and Georgia) in Managing Intellectual Property's (MIP) IP STARS guide and is consistently recommended by Intellectual Asset Management (IAM) Patent 1000 for his Patent Litigation expertise, strategic judgment, and technical knowledge. Best Lawyers also recognizes David in the practice areas of Biotechnology and Life Sciences Practice and Litigation-Patent and BTI Consulting Group named him a Client Service All-Star based on direct client feedback.
David earned his doctorate in organic chemistry from Emory University and later served as a National Institutes of Health (NIH) postdoctoral fellow at Columbia University. He subsequently earned his juris doctor (J.D.) from Emory University School of Law, where he was a Robert W. Woodruff Fellow and received numerous academic honors.
Order of the Coif.
Judicial intern for the Honorable Chief Justice Hugh P. Thompson, Supreme Court of Georgia, 2010.
Judicial intern for the Honorable Elizabeth E. Long and the Honorable Alice D. Bonner, Fulton County Superior Court's Business Case Division, 2010.
Coauthor. "Securing and Maintaining a Strong Patent Portfolio for Pharmaceuticals," Medicinal Chemistry Letters, 2019.
Coauthor. "Carboxylated, Heteroaryl-Substituted Chalcones as Inhibitors of Vascular Cell Adhesion Molecule-1 Expression for Use in Chronic Inflammatory Diseases," Journal of Medicinal Chemistry, 2007.
Coauthor. "An Efficient Synthesis of a Dual PPAR alpha/gamma Agonist and the Formation of a Sterically Congested alpha-Aryloxyisobutyric Acid Via a Bargellini Reaction," Journal of Organic Chemistry, 2005.
Coauthor. "Enantioselective Resolving Resins from a Combinatorial Library. Kinetic Resolution of Cyclic Amino Acid Derivatives," Journal of the American Chemical Society, 1998.
Coauthor. "Tweezers with Different Bite: Increasing the Affinity of Synthetic Receptors by Varying the Hinge Part," Angewandte Chemie International Edition (English), 1998.
Genzyme Corporation v. Sarepta Therapeutics, Inc. et al.
Representing Sarepta in defensive patent litigation involving Elevidys®, a one-time gene therapy for the treatment of a neuromuscular disease known as Duchenne muscular dystrophy (DMD) and in parallel offensive inter partes reviews (IPRs).
1:24-cv-00882, D. Del., Judge Andrews
Novartis Pharmaceuticals Corporation et al. v. Fresenius Kabi USA, LLC et al.
Trial counsel for Novartis in district court litigation against multiple generics related to KISQALI ®, a blockbuster, breakthrough CDK4/6-inhibitor for the treatment of breast cancer. After a bench trial, the case resulted in a favorable settlement for our client, supporting patent protection at least until 2031.
1:21-cv-00870, D. Del., Judge Hall
Successfully represented Bausch & Lomb and Eye Therapies in a Hatch-Waxman patent infringement litigation and parallel PTAB challenges concerning an ANDA for generic versions of over-the-counter Lumify® ocular drops. The cases settled favorably for our clients.
3:21-cv-16766, D.N.J., Judges Kirsch, Singh
IPR2022-00146, PTAB, Judges Hulse, New, Pollock
IPR2024-00467, PTAB, Judges Flax, Pollock, Yang
IPR2022-00142, PTAB, Judges Flax, Hulse, New, Pollock
Incyte Corporation et al. v. Sun Pharmaceutical Industries Limited et al.
Successfully represented Incyte in patent litigation, including preliminary injunction proceedings related to Sun Pharmaceuticals’ deuterated Janus kinase (JAK) inhibitor, LEQSELVI™. Case settled favorably for our client.
2:24-cv-06944, D.N.J., Judge Padin
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Successfully defended Novartis against Genzyme’s multiple patent infringement actions and inter partes review (IPR) proceedings related to recombinant adeno-associated virus vector technology used in Novartis’ blockbuster, breakthrough gene therapy Zolgensma®. The case settled after four patents were invalidated during claim construction, five patents found not literally infringed, and institution of multiple IPRs.
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.
3:19-cv-13955, 3:19-cv-16305, D.N.J., Judges Wolfson, Arpert
Workshop
Protecting Innovation in the Life Sciences: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law Protecting Innovation in the Life Sciences: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 7, 2026
Cambridge
Conference
Georgia Life Sciences Summit 2025 Georgia Life Sciences Summit 2025
August 26-27, 2025
Sandy Springs
Conference
4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA 4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
October 8-24, 2024
Virtual
“David Weingarten is distinguished for his rare blend of medicinal chemistry expertise and strategic legal execution.”
Intellectual Asset Management Patent 1000
“‘David has developed a patent strategy that gives us freedom to operate and protects us from infringement, and his experience as a medicinal chemist is invaluable because he understands in detail the formulation, process development and use of the technology.’”
Intellectual Asset Management Patent 1000
"We are extremely impressed with [David's] deep understanding of the chemistry... as well as the drug development process. His guidance has brought tremendous value to us as a company as we strengthen our patent portfolio and efficiently develop medical innovations."
Intellectual Asset Management Patent 1000
“The Atlanta office is not short of litigation firepower; John Livingstone and David Weingarten are other compelling advocates, particularly in the context of major pharmaceutical and biotechnology cases.”
Intellectual Asset Management Patent 1000
"David Weingarten is outstanding! His recommendations are well thought-out, clear, concise, and strategic. He is an experienced medicinal chemist as well as an outstanding lawyer, and his experience in working on chemistry issues with both large pharma and small biotechs gives him a perspective beyond that of most IP lawyers."
The Legal 500 U.S.
"Armed with a PhD in organic chemistry, David Weingarten masters the intricate details of a case."
Intellectual Asset Management Patent 1000
“David Weingarten loves the science and he gives even the most tenured experts a run for their money.”
The Legal 500 U.S.
“David develops a respectful partnership with his clients. We feel like partners, not just cases.."
BTI Client Service All-Stars
“David Weingarten is distinguished for his rare blend of medicinal chemistry expertise and strategic legal execution.”
Intellectual Asset Management Patent 1000
“‘David has developed a patent strategy that gives us freedom to operate and protects us from infringement, and his experience as a medicinal chemist is invaluable because he understands in detail the formulation, process development and use of the technology.’”
Intellectual Asset Management Patent 1000
"We are extremely impressed with [David's] deep understanding of the chemistry... as well as the drug development process. His guidance has brought tremendous value to us as a company as we strengthen our patent portfolio and efficiently develop medical innovations."
Intellectual Asset Management Patent 1000
“The Atlanta office is not short of litigation firepower; John Livingstone and David Weingarten are other compelling advocates, particularly in the context of major pharmaceutical and biotechnology cases.”
Intellectual Asset Management Patent 1000
"David Weingarten is outstanding! His recommendations are well thought-out, clear, concise, and strategic. He is an experienced medicinal chemist as well as an outstanding lawyer, and his experience in working on chemistry issues with both large pharma and small biotechs gives him a perspective beyond that of most IP lawyers."
The Legal 500 U.S.
"Armed with a PhD in organic chemistry, David Weingarten masters the intricate details of a case."
Intellectual Asset Management Patent 1000
“David Weingarten loves the science and he gives even the most tenured experts a run for their money.”
The Legal 500 U.S.
“David develops a respectful partnership with his clients. We feel like partners, not just cases.."
BTI Client Service All-Stars
Award/Ranking
Finnegan Wins “Hatch-Waxman Litigation Firm of the Year – Branded” and David Weingarten Wins “Patent Strategy Attorney of the Year (South)” at the LMG Life Sciences Americas Awards Finnegan Wins “Hatch-Waxman Litigation Firm of the Year – Branded” and David Weingarten Wins “Patent Strategy Attorney of the Year (South)” at the LMG Life Sciences Americas Awards
September 11, 2026
LMG Life SciencesAward/Ranking
31 Finnegan Attorneys Recognized by Best Lawyers 2027 31 Finnegan Attorneys Recognized by Best Lawyers 2027
August 20, 2026
Best LawyersAward/Ranking
Finnegan Receives Tier 1 Rankings from Managing IP; More than 30 Attorneys Named 2026 IP Stars Finnegan Receives Tier 1 Rankings from Managing IP; More than 30 Attorneys Named 2026 IP Stars
July 30, 2026
Managing Intellectual PropertyAward/Ranking
Finnegan Shortlisted in 13 Categories at the 2026 LMG Life Sciences America Awards Finnegan Shortlisted in 13 Categories at the 2026 LMG Life Sciences America Awards
July 15, 2026
LMG Life SciencesAward/Ranking
Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked
May 28, 2026
Intellectual Asset Management (IAM)Award/Ranking
Finnegan Receives More Than 20 Nominations for the 2026 Managing IP Americas Awards Finnegan Receives More Than 20 Nominations for the 2026 Managing IP Americas Awards
February 11, 2026
Managing Intellectual PropertyCourt of Appeals, Georgia
U.S. District Court, N.D. Georgia
U.S. Court of Appeals, Federal Circuit
U.S. Court of Appeals, Veterans Claims
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.